Personalized vaccine trial offers new hope for advanced kidney cancer patients
Disease control
Not yet recruiting
This is a very early study to check the safety and initial effects of a new personalized vaccine called KSD-201 for people with advanced kidney cancer that has stopped responding to standard treatments. Doctors will make the vaccine from the patient's own immune cells and give it…
Phase: EARLY_PHASE1 • Sponsor: Kousai Bio Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC